 |
 |

DNA Vaccination May Open Up a New Avenue for Treatment of Alzheimer Disease
Arch Neurol. 2004;61:1832.
 |
 |
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
 |
 |
Accumulation of amyloid- (A 40 42) peptides that are generated by proteolytic processing of amyloid precursor protein is widely considered to play a major role in the neurodegeneration of Alzheimer disease (AD), and the amelioration of amyloid burden is a hot target for the treatment of AD. Immunization by A 42 peptide has been demonstrated to lead to reduction of A burden accompanied by improved cognitive performance in a mouse transgenic model of AD.1 This approach of A 42 peptide immunization has been applied in a clinical trial of patients with AD. About 300 patients with AD received multiple doses of the A 42 peptide with the adjuvant QS21. Although patients with higher antibody titer (20%) seemed to show a slowing of the cognitive decline, the program was discontinued owing to the fact that about 6% of treated patients developed autoimmune meningoencephalitis.2-4 This experience suggests that A 42 peptide immunization is potentially an effective treatment . . . [Full Text of this Article]AUTHOR INFORMATION
Shoji Tsuji, MD, PhD
CiteULike Connotea Delicious Digg Facebook Reddit Technorati Twitter
What's this?
RELATED ARTICLE
Gene Vaccination to Bias the Immune Response to Amyloid- Peptide as Therapy for Alzheimer Disease
Baoxi Qu, Roger N. Rosenberg, Liping Li, Philip J. Boyer, and Stephen A. Johnston
Arch Neurol. 2004;61(12):1859-1864.
ABSTRACT
| FULL TEXT
|